Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
85(c) 83.09(c) 82.34(c) 82.17(c) 83.38(c) Last
12 871 440 9 664 704 9 631 524 10 845 849 9 632 141 Volume
+2.37% -2.25% -0.90% -0.21% +1.47% Change
More quotes
Financials (USD)
Sales 2020 48 200 M - -
Net income 2020 12 144 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,6x
Yield 2020 2,94%
Sales 2021 51 713 M - -
Net income 2021 13 239 M - -
Net Debt 2021 12 384 M - -
P/E ratio 2021 15,6x
Yield 2021 3,13%
Capitalization 211 B 211 B -
EV / Sales 2020 4,69x
EV / Sales 2021 4,32x
Nbr of Employees 71 000
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MERCK & CO., INC.
01/14Philips Partners with Merck to Develop Digital Systems for Fertility Treatmen..
MT
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
01/13MERCK : Confirms Agreement with UNICEF to Establish the World's First Global Ebo..
PU
01/12EISAI : To present data on lenvima monotherapy and in combination with keytruda ..
AQ
01/12MERCK : Gets FDA Priority Review of V114 Vaccine for Adults
DJ
01/12MERCK : Says FDA Accepts for Priority Review the Biologics License Application f..
MT
01/12MERCK : U.S. FDA Accepts for Priority Review the Biologics License Application f..
BU
01/11MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
AQ
01/08Merck Create Advisory Panel to Address Company-Wide Digital Ethics
MT
01/08MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
BU
01/06CEOs Consider Ways to Smooth the Presidential Transition, Including Holding B..
DJ
01/05MERCK : Partners With Symvivo on BacTRL Platform Technology
MT
01/05Equities Climb in Early US Trading Led by Rise in Energy Sector as Oil Prices..
MT
01/04MERCK : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020MERCK : LYNPARZA Receives Three New Approvals in Japan
AQ
More news
News in other languages on MERCK & CO., INC.
01/14Bayer hofft auf Wachstumsschub mit Gen- und Zelltherapien
01/12MERCK : le V114 obtient une revue prioritaire de la FDA
01/11Vereinte Nationen legen Vorrat für Ebola-Impfstoff an
01/06MÄRKTE USA/"Blaue Welle" trägt Dow erstmals über 31.000er Marke
01/06MÄRKTE USA/Erwartung weiterer Stimuli sorgt für Rekordlaune
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC - 2020
Good timing to go long again
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,95 $
Last Close Price 83,38 $
Spread / Highest target 28,3%
Spread / Average Target 16,3%
Spread / Lowest Target 1,94%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.1.93%210 954
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120